Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
about
Diagnosis and treatment of deep-vein thrombosisMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismUnresolved issues in anticoagulant therapyLow molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series.Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAnti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.Prevention of venous thromboembolism in obesity.The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.Low molecular weight heparin in pregnancy: current issues.Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.Clinical and critical care concerns in severely ill obese patient.Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenProphylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus
P2860
Q24673847-21A6B124-03D4-4AC5-812F-23127D6714BDQ26992262-2D503FD3-D269-44D0-BA4E-B207C9DC72B4Q28079081-A73A5F20-94B4-4D6D-9CA1-172944CB2C54Q28196778-CA5C2694-2E72-4DAB-8D9B-41D6962A7864Q33344373-448C2131-2659-42B3-AEAC-7E9465897B7FQ33383622-3830441A-55D7-466C-B351-FE33B1899016Q33399576-04DE35D6-24A6-436D-858B-1C3CC8E666C4Q34999668-85451958-A69F-4C74-97E9-E81B2A9AB42BQ35633708-81BB7325-F53B-468F-BB60-6284923F9D50Q36000885-9645BC5A-0BD0-4774-8A5B-CE22D74AD30DQ36051434-AD9C0214-D823-4821-ABE1-C69798F5DB63Q36205646-671E9E1B-90A0-4741-87EE-6424243C71AEQ36331619-244EF5DA-3329-4EFA-A79C-0BEA6B95E185Q36510063-ACC9431B-D388-41E9-AF63-C447FA7466BAQ37453595-21411CFC-4D3D-4A4C-880E-4A44A7DCF77BQ38000240-B91B2188-27A4-4088-9906-F9643D0AF00DQ59126194-0E7A530F-F6A2-4CCC-8BAA-B5E314AD126A
P2860
Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Effect of patient weight on th ...... ent of venous thromboembolism.
@en
Effect of patient weight on th ...... ent of venous thromboembolism.
@nl
type
label
Effect of patient weight on th ...... ent of venous thromboembolism.
@en
Effect of patient weight on th ...... ent of venous thromboembolism.
@nl
prefLabel
Effect of patient weight on th ...... ent of venous thromboembolism.
@en
Effect of patient weight on th ...... ent of venous thromboembolism.
@nl
P2093
P356
P1476
Effect of patient weight on th ...... ent of venous thromboembolism.
@en
P2093
P356
10.1159/000048043
P577
2001-01-01T00:00:00Z